DrugPatentWatch Database Preview
ALUNBRIG Drug Profile
Which patents cover Alunbrig, and what generic alternatives are available?
Alunbrig is a drug marketed by Ariad and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-five patent family members in sixteen countries.
The generic ingredient in ALUNBRIG is brigatinib. Two suppliers are listed for this compound. Additional details are available on the brigatinib profile page.
Summary for ALUNBRIG
| International Patents: | 25 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 24 |
| Clinical Trials: | 4 |
| Drug Prices: | Drug price information for ALUNBRIG |
| DailyMed Link: | ALUNBRIG at DailyMed |
Generic Entry Opportunity Date for ALUNBRIG
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ALUNBRIG
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Tyrosine Kinase Inhibitors Cytochrome P450 3A Inducers |
Synonyms for ALUNBRIG
| (2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone |
| (2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide |
| 1197953-54-0 |
| 1350848-43-9 |
| 1574359-10-6 |
| 2,4-Pyrimidinediamine, 5-chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)- |
| 5-Chloro-N~4~-[2-(Dimethylphosphoryl)phenyl]-N~2~-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl)piperidin-1-Yl]phenyl}pyrimidine-2,4-Diamine |
| 5-Chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1- yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine |
| 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-Pyrimidinediamine |
| 6GY |
| AKOS030257612 |
| Alunbrig (TN) |
| AP 26113 |
| AP-26113 |
| BDBM50185140 |
| Brigatinib |
| Brigatinib (AP26113) |
| Brigatinib (USAN) |
| Brigatinib [USAN:INN] |
| Brigatinib [USAN] |
| CHEMBL3545311 |
| CS-4278 |
| D10866 |
| DB12267 |
| EX-A775 |
| FT-0700112 |
| HY-12857 |
| HYW8DB273J |
| KS-00000TSQ |
| MFCD29472221 |
| MolPort-044-561-640 |
| S8229 |
| SCHEMBL11916361 |
| UNII-HYW8DB273J |
| ZINC148723177 |
US Patents and Regulatory Information for ALUNBRIG
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-002 | Apr 28, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-003 | Oct 2, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for ALUNBRIG
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Israel | 208716 | ➤ Sign Up |
| European Patent Office | 3210609 | ➤ Sign Up |
| Japan | 2015163621 | ➤ Sign Up |
| Canada | 2723961 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
